NCT01898585 - An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 17, 2013

Primary Completion Date

May 22, 2019

Study Completion Date

May 22, 2019

Conditions

Malignant Melanoma

Interventions

DRUG

Zelboraf

Vemurafenib 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.

Trial Locations (9)

2196

Medical Oncology Centre of Rosebank; Oncology, Johannesburg

Sandton Oncology Medical Group, Sandton

6529

Cancercare, George

7506

Groote Schuur Hospital ( Uni of Capetown ); Oncology Dept, Cape Town

7570

Cape Town Oncology Trials, Cape Town

7700

Cancercare, Cape Town

9301

National Hospital; Oncotherapy Dept, Bloemfontein

0181

Mary Potter Oncology Centre, Groenkloof

0002

University of Pretoria; Department of Medical Oncology, Pretoria

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY